Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing incidence of cancer and rheumatoid arthritis
3.2.1.2 Growing regulatory approvals for injectable cytotoxic drugs
3.2.1.3 Increasing investments for the development of precision oncology therapies
3.2.1.4 Rapid increase in cancer care facilities
3.2.2 Industry pitfalls & challenges
3.2.2.1 High drug development cost
3.2.2.2 Presence of strong alternative therapies
3.3 Growth potential analysis
3.4 Future market trends
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Antimetabolites
5.3 Vinca alkaloids
5.4 Taxanes
5.5 Anthracyclines
5.6 Platinum compounds
5.7 Alkylating agents
5.8 Other drug classes
Chapter 6 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Hospital pharmacies
6.3 Retail pharmacies
6.4 Online pharmacies
Chapter 7 Market Estimates and Forecast, By Application, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Oncology
7.3 Rheumatoid arthritis
7.4 Multiple sclerosis
7.5 Other applications
Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Netherlands
8.3.7 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Rest of Latin America
8.6 Middle East and Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 Abbvie Inc
9.2 Accord Healthcare, Inc.
9.3 Amgen, Inc.
9.4 Baxter International Inc.
9.5 Bristol-Myers Squibb Company
9.6 Eli Lilly and Company
9.7 F. Hoffmann-La Roche Ltd.
9.8 Fresenius Kabi AG
9.9 Johnson and Johnson Services Inc.
9.10 Merck & Co. Inc.
9.11 Novartis AG
9.12 Pfizer, Inc.
9.13 Sanofi
9.14 Takeda Pharmaceutical Company Limited
9.15 Teva Pharmaceutical Industries Ltd.
